BiotechTube

Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

HIV

Conditions

HIV, AIDS, Kaposi's Sarcoma, Human Herpesvirus 8

Trial Timeline

Jan 1, 2003 → Mar 1, 2009

NCT ID
NCT00380770

About Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV

Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is a approved stage product being developed by Cipla for HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00380770. Target conditions include HIV, AIDS, Kaposi's Sarcoma.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00380770ApprovedCompleted

Competing Products

20 competing products in HIV

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
77
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tabletShionogiPhase 1
33
GW810781ShionogiPhase 2
52
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mgEli LillyPhase 2
52
Epoetin alfaJohnson & JohnsonPre-clinical
23
LevofloxacinJohnson & JohnsonPhase 1
33
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
33
ABBV-181 + PlaceboAbbViePhase 1
33
ABBV-382 + ABBV-382 + Placebo for ABBV-382AbbViePhase 1
33
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
85
lopinavir/ritonavir + lamivudineAbbViePre-clinical
23
Lopinavir/RitonavirAbbVieApproved
85
Budigalimab + Placebo + Budigalimab + PlaceboAbbViePhase 1
33
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + BudigalimabAbbViePhase 2
52
CVC 150 mg + CVC 300 mgAbbViePhase 2
52
Rosuvastatin 10 mg. daily for 96 weeks + PlaceboAstraZenecaPhase 2
52
Raltegravir + Placebo + Current ARTMerckPhase 3
77
Indinavir sulfate + Lamivudine + ZidovudineMerckPhase 3
77
RosuvastatinAstraZenecaPhase 2
52

Other Products from Cipla

Insulin Lispro-aabc + Insulin GlargineApproved
85
CBT124 + EU-sourced Avastin® + Carboplatin + PaclitaxelPhase 3
77
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboPhase 3
77